zimlovisertib (PF-06650833) / Pfizer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zimlovisertib (PF-06650833) / Pfizer
NCT04092452: A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Completed
2a
194
Canada, US, RoW
PF-06650833, PF-06700841, PF-06826647, Placebo
Pfizer
Acne Inversa
01/22
01/22
NCT02996500 / 2016-002337-30: Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Checkmark From trial in rheumatoid arthritis
Nov 2019 - Nov 2019: From trial in rheumatoid arthritis
Completed
2
269
Europe, US, RoW
PF-06650833, Placebo, Tofacitinib, Xeljanz
Pfizer
Rheumatoid Arthritis
08/18
08/18
NCT04575610: IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

Terminated
2
7
US
PF-06650833, Placebo
Yale University, Pfizer
COVID-19
10/21
10/21
NCT04413617 / 2019-002676-14: TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Completed
2
460
Europe, Canada, RoW
PF-06650833, PF-06651600, Tofacitinib
Pfizer
Rheumatoid Arthritis
02/22
02/22
PNA-COV, NCT04933799: IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

Recruiting
2
68
US
PF-06650833, IRAK 4 inhibitor, Matching Placebo, Placebo
Giovanni Franchin, M.D, Ph.D, Pfizer
COVID-19 Pneumonia
03/22
05/22

Download Options